Martin Brauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Martin Brauer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A. Günther
Universitätsklinikum Jena
1 shared publicationA. Rahmel
Deutsche Stiftung Organtransplantation (DSO)
1 shared publication- Albrecht Günther
Department of Neurology, University Hospital Jena, Jena, Germany
1 shared publication - Anke Werner
Department of Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany
1 shared publication - Anne Gunkel
Department of Neurology, Jena University Hospital, 07747 Jena, Germany
1 shared publication C. Wachsmuth
Deutsche Stiftung Organtransplantation (DSO)
1 shared publication
Latest Publications
- Open Access
- 28 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (21) , 2734
Brain Perfusion Scintigraphy in the Diagnostic Toolbox for the Confirmation of Brain Death: Practical Aspects and Examination Protocol
Background: In addition to clinical examinations, confirmatory investigations are frequently performed to determine brain death (BD). Among other perfusion tests, brain perfusion scintigraphy (BPS) has been shown to be a reliable tool for the detection of brain circulatory arrest, particularly in cases with inconclusive clinical status or potential pharmacological interactions. Methods: Evaluation for brain death included standardized clinical examinations by two experienced neuro-intensive medicine specialists, followed by ancillary brain perfusion tests. BPS with the lipophilic tracer 99mTc-hexamethylpropyleneamine oxime (HMPAO) was performed according to a standardized protocol. Imaging results, additional confirmatory test results, as well as clinical parameters were prospectively recorded. Results: BPS was performed in 30 patients (18 male, 12 female; median age 55.5 years, range 0.1–79.8 years). Eight patients underwent decompressive craniectomy (DC) prior to BD evaluation, three patients were supported by veno-arterial extracorporeal membrane oxygenation (vaECMO), and one patient by a left ventricular assist device (LVAD). The median interval between the initial brain-damaging event and BPS was 4.0 days (range 1–18 days). BPS demonstrated brain perfusion cessation in all patients. A concomitant single-photon emission computed tomography (SPECT) was required in one patient. There were no technical failures requiring a re-examination. Conclusions: BPS is a feasible, safe, and technically robust confirmatory test in BD diagnosis. BPS yielded unambiguous results, particularly in cases with inconclusive results of other ancillary tests, in neonates, young children and patients after DC. It is applicable to patients supported by LVAD and vaECMO.
- 28 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (21) , 2734
Open AccessBrain Perfusion Scintigraphy in the Diagnostic Toolbox for the Confirmation of Brain Death: Practical Aspects and Examination Protocol
Background: In addition to clinical examinations, confirmatory investigations are frequently performed to determine brain death (BD). Among other perfusion tests, brain perfusion scintigraphy (BPS) has been shown to be a reliable tool for the detection of brain circulatory arrest, particularly in cases with inconclusive clinical status or potential pharmacological interactions. Methods: Evaluation for brain death included standardized clinical examinations by two experienced neuro-intensive medicine specialists, followed by ancillary brain perfusion tests. BPS with the lipophilic tracer 99mTc-hexamethylpropyleneamine oxime (HMPAO) was performed according to a standardized protocol. Imaging results, additional confirmatory test results, as well as clinical parameters were prospectively recorded. Results: BPS was performed in 30 patients (18 male, 12 female; median age 55.5 years, range 0.1–79.8 years). Eight patients underwent decompressive craniectomy (DC) prior to BD evaluation, three patients were supported by veno-arterial extracorporeal membrane oxygenation (vaECMO), and one patient by a left ventricular assist device (LVAD). The median interval between the initial brain-damaging event and BPS was 4.0 days (range 1–18 days). BPS demonstrated brain perfusion cessation in all patients. A concomitant single-photon emission computed tomography (SPECT) was required in one patient. There were no technical failures requiring a re-examination. Conclusions: BPS is a feasible, safe, and technically robust confirmatory test in BD diagnosis. BPS yielded unambiguous results, particularly in cases with inconclusive results of other ancillary tests, in neonates, young children and patients after DC. It is applicable to patients supported by LVAD and vaECMO.
- Open Access
- 22 February 2022
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 36, 101614
Rescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
- 22 February 2022
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 36, 101614
Open AccessRescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effect
- 16 November 2018
- Published by Springer Nature in Der Anaesthesist
- Vol. 68 (1) , 22-29
Wie viele potenzielle Organspender gibt es wirklich?
- 16 November 2018
- Published by Springer Nature in Der Anaesthesist
- Vol. 68 (1) , 22-29
Wie viele potenzielle Organspender gibt es wirklich?